Sosei appoints Andrew Oakley as CFO
Sosei Group Corporation announces the appointment of Andrew Oakley as Chief Financial Officer (CFO) effective from February 1 2017. Mr Oakley will be based in Sosei’s Tokyo offices. Mr Oakley will succeed Mr Hidetoshi Torami who has resigned from Sosei for personal reasons.
Mr Oakley, a Chartered Accountant with an MBA from London Business School, has had a wide and varied financial career and over the past 14 years has held CFO positions in several publicly listed biotechnology companies including Actelion Ltd, Novimmune SA, and most recently at Vectura Group plc, where he was also a member of the Board.
Commenting on the appointment, Peter Bains, CEO at Sosei, said: "Andrew brings a wealth of global corporate finance experience, expertise and leadership with a particularly strong focus in the biotechnology sector. I am delighted to welcome him to Sosei as our new CFO and look forward to working with Andrew in the coming years as we seek to build Sosei into a global presence"
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.